Endocrine Abstracts (2012) 28 SE1.3

UK stance on adult GH replacement maintains our isolation from Europe

Stephen Shalet

Endocrinology, Christie Hospital, Manchester, United Kingdom.

In adults severe GH deficiency has been a registered indication for the use of GH replacement since 1996. The UK prescribing policy has focused on a single biological endpoint, quality of life, whilst other European countries have adopted a holistic approach. How did this come about, why does the UK differ from its European neighbours, and is the UK practice satisfactory from an Endocrinologist's perspective ?

Declaration of interest: There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding: No specific grant from any funding agency in the public, commercial or not-for-profit sector.

Article tools

My recent searches

No recent searches.